Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron Pharma Completes $31M Series C Financing
Top venture syndicate invests to advance expanding pipeline of products that modulate tissue growth and repair
View HTML
Toggle Summary Technology Review: Mimicking the Massively Muscular
Technology Review: Mimicking the Massively Muscular Link to article
View HTML
Toggle Summary Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
Findings Substantiate Potential of ACE-031 in Treatment of Neuromuscular Disease and Cancer-related Muscle Loss
View HTML
Toggle Summary Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association
Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association Cambridge, Mass. – October 4, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle,
View HTML
Toggle Summary Acceleron Pharma to Present at the Natixis Bleichroeder Hidden Gems Conference
Acceleron Pharma to Present at the Natixis Bleichroeder Hidden Gems Conference Cambridge, Mass. – October 2, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf,
View HTML
Toggle Summary Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research
Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research Cambridge, Mass. – September 24, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Niels
View HTML
Toggle Summary Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates
Acceleron Pharma’s ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates Cambridge, Mass. – September 20, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and
View HTML
Toggle Summary Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference
Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference Cambridge, Mass. – September 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf,
View HTML
Toggle Summary Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer
Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer Cambridge, MA – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John L.
View HTML
Toggle Summary Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
Encouraging safety and biological activity supports advancement into phase 2 studies
View HTML